Milbemax tasty chewable tablet 12,5 mg/125 mg | dog M | 12x4 tabl.

The Milbemax tasty chewable tablet is a worming product for dogs. The product can be used for the treatment of mixed infections with adult tapeworms and roundworms. The product can also be used in the prevention of heartworm disease, if simultaneous treatment against tapeworms is required. The chewable tablet should be taken orally with or after some food.

The chewable tablet looks like a biscuit and has a nice chicken flavour. As a result almost all dogs eat the tablet just from the hand. The Milbemax chewable tablet makes worming a treat!

The Milbemax tasty chewable tablet for dogs is suitable for dogs weighing at least 5 kg. The chewable tablet should not be administered to dogs weighing less than 5 kg. The dosage is determined on the basis of the body weight of the dog.

Leaflet Milbemax chewable tablets for dogs

USES
It is indicated in the dog for the treatment of mixed infections  by adult cestodes and nematodes of the following species:

• Cestodes: Dipylidium caninum, Taenia spp., Echinococcus spp., Mesocestoides spp
• Nematodes: Anclystoma caninum, Toxocara canis, Toxascaris leonina, Trichuris vulpis.

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis), if concomitant treatment against cestodes is indicated.

CONTRA-INDICATIONS
Do not use in dogs weighing less than 5 kg.
Do not use in case of hypersensitivity to the active substances or to any of the excipients.

Pregnancy and lactation
Milbemax can be used in pregnant and lactating bitches and in breeding animals.

DOSAGE AND ADMINISTRATION

The product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:

In cases where heartworm disease prevention is used and at the same time treatment against tapeworm is required, the product can replace the monovalent product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the product and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

PRECAUTIONS FOR USE
Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in cases where it is known that a dog has been travelling to and from heartworm risk regions, before using MILBEMAX, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the product.
Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.
No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.
In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
In very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, drooling, diarrhoea and anorexia) have been observed in dogs after administration of Milbemax.
The adverse reactions observed following an overdose are the same as those observed at the recommended dose but more pronounced.
Interaction with other medicinal products and other forms of interaction The concurrent use of the product with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the product at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the product and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.
Wash hands after use.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Storage precaution
Do not store above 25°C.
Keep out of the reach and sight of children.